Becton, Dickinson and Company (BDX)
(Delayed Data from NYSE)
$233.25 USD
-3.09 (-1.31%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $233.15 -0.10 (-0.04%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$233.25 USD
-3.09 (-1.31%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $233.15 -0.10 (-0.04%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Zacks News
Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.
BD (BDX) Gears Up for Q1 Earnings: What's in the Offing?
by Zacks Equity Research
BD's (BDX) first-quarter fiscal 2021 results are likely to reflect strong year-over-year growth in revenues from assays in its Life Sciences segment.
Becton, Dickinson's (BDX) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Becton, Dickinson and Company (BDX).
The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Becton, Dickinson and Co, Quidel and Hologic
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Becton, Dickinson and Co, Quidel and Hologic
Federal, Private Tie-Ups Boost COVID-19 Testing Volume
by Urmimala Biswas
The Department of Health and Human Services (HHS) promises over $22 billion of funding.
BD (BDX) Posts Upbeat Preliminary Fiscal First Quarter Results
by Zacks Equity Research
BD (BDX) projects its fiscal Q1 revenues to surge from the year-ago figure, primarily on the back of high demand for its COVID-19 diagnostic tests
Testing Space in Focus Again Thanks to New Wave of Coronavirus
by Urmimala Biswas
The resurgence in coronavirus infections is drawing attention back to the diagnostic testing space.
Why Becton Dickinson (BDX) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Invest in LHC Group (LHCG) Stock Now
by Zacks Equity Research
LHC Group (LHCG) continues to gain traction from its broad range of services, and strategic acquisitions and joint ventures.
AMN Healthcare (AMN) Releases Solid Preliminary Q4 Revenues
by Zacks Equity Research
AMN Healthcare (AMN) posts solid fourth-quarter 2020 revenue data on the back of strong demand for the company's services across its three segments.
The Zacks Analyst Blog Highlights: McKesson, Cardinal Health, Becton, Dickinson and Co and Hill-Rom Holdings
by Zacks Equity Research
The Zacks Analyst Blog Highlights: McKesson, Cardinal Health, Becton, Dickinson and Co and Hill-Rom Holdings
4 Dividend-Paying Undervalued MedTech Stocks for Gains in 2021
by Urmimala Biswas
Here we discuss four dividend-paying value stocks, MCK, CAH, BDX and HRC, which though trading cheap now, have solid chances of a rebound in the second half of 2021.
Why Is Becton Dickinson (BDX) Up 3.5% Since Last Earnings Report?
by Zacks Equity Research
Becton Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should Value Investors Choose Becton, Dickinson (BDX) Stock?
by Zacks Equity Research
Let's see if Becton, Dickinson (BDX) stock is a good choice for value-oriented investors right now from multiple angles.
BD (BDX) to Boost Pre-Fillable Syringe-Manufacturing Capacity
by Zacks Equity Research
BD (BDX) is set to improve its pre-fillable syringe-manufacturing ability with its expansion and upgrade plans.
Pediatric Medical Space Thrives Amid COVID-19: 3 Stocks in Focus
by Zacks Equity Research
Among several domains within the MedTech space, several pediatric medical device stocks have been gaining traction amid the coronavirus pandemic
Becton Dickinson (BDX) Buys Medical Business Assets of CUBEX
by Zacks Equity Research
This should further boost BD's (BDX) Medical segment.
Becton Dickinson (BDX) Earnings Surpass Estimates in Q4
by Zacks Equity Research
Within the United States, Becton Dickinson's (BDX) Diagnostic Systems unit witnessed strong revenue growth in the fiscal fourth quarter.
Becton Dickinson (BDX) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 11.60% and 6.68%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Nov 5 Earnings Roster: BDX, ABC & More
by Trina Mukherjee
Medical Product companies have shown strength in the third quarter on the back of huge adoption of COVID-19 related healthcare-support products and services despite the impact of the ongoing pandemic.
What's in Store for Becton, Dickinson's (BDX) Q4 Earnings?
by Zacks Equity Research
Becton, Dickinson's (BDX) fiscal fourth-quarter results likely to reflect robust performance at BD Life Sciences.
Analysts Estimate Becton Dickinson (BDX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Dental Supplies Stocks Set to Shine on the Industry's Upturn
by Trina Mukherjee
Despite the challenges thrown by the COVID-19 pandemic, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical - Dental Supplies industry. CAH, WST and MCK are well positioned to gain from the prospects.
LabCorp (LH) Extends Pact With Swedish for Coronavirus Lab Service
by Zacks Equity Research
Under the extended alliance, LabCorp (LH) expects to expand its COVID-19 test capacity in the Seattle area.
BD's (BDX) COVID-19 Real-Time PCR Detection Kit Gets CE Mark
by Zacks Equity Research
BD's (BDX) Real Time PCR Detection Kit enables BD MAX System users to run a single module that tests concurrently for COVID-19, flu and RSV.
OPKO Health's (OPK) BioReference Laboratories Unveils New Test
by Zacks Equity Research
OPKO Health's (OPK) BioReference Laboratories' new multiplex test can differentiate between COVID-19 and Influenza infections with a single sample.